Artesunate and artelinic acid: Association of embryotoxicity, reticulocytopenia, and delayed stimulation of hematopoiesis in pregnant rats

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 92, Issue 1, 2011, Pages 52-68

  Clark, Robert L ^a   Brannen, Kimberly C ^b   Sanders, James E ^c   Hoberman, Alan M ^b  

^a Artemis Pharmaceutical Research   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

^c New Entity Consulting Inc   (United States)

Author keywords

Artelinic acid; Artemisinin antimalarial; Artesunate; Embryotoxicity; Hematopoiesis; Reticulocytopenia

Indexed keywords

ARTELINIC ACID; ARTESUNATE; HEMOGLOBIN; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASOPHIL; BLOOD SAMPLING; BONE MARROW CELL; CELL DAMAGE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOSE RESPONSE; EMBRYO; EMBRYO CELL; EMBRYO DEATH; EMBRYO DEVELOPMENT; EMBRYOTOXICITY; ERYTHROBLAST; ERYTHROCYTE COUNT; FEMALE; GESTATION PERIOD; HEMATOCRIT; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MEAN CORPUSCULAR VOLUME; MITOCHONDRION; MONOCYTE; NEUTROPHIL COUNT; NONHUMAN; PREGNANCY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRENATAL EXPOSURE; PRIORITY JOURNAL; RAT; RETICULOCYTE COUNT; RETICULOCYTOPENIA; THROMBOCYTE COUNT;

ANIMALS; ARTEMISININS; BODY WEIGHT; EMBRYO, MAMMALIAN; FEMALE; HEMATOPOIESIS; LEUKOCYTE COUNT; LITTER SIZE; PLATELET COUNT; PREGNANCY; RATS; RETICULOCYTE COUNT; RETICULOCYTES; SPLEEN; TOXICITY TESTS;

ANIMALIA; ARTESUNATE; RATTUS;

EID: 79751503440     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.20282     Document Type: Article

References (115)

1. Ashley EA, White NJ. 2005. Artemisinin-based combinations. Curr Opin Infect Dis 18:531-536.
2. Austin CD, Wen X, Gazzard L, et al. 2005. Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci USA 102:17987-17992.
3. Bialek R, Knobloch J. 1999. Parasitic diseases in pregnancy and congenital parasitosis. Part I: protozoan infections (Review, German). Zeitschrift fur Geburtshilfe und Neonatologie 203:55-62.
4. Blanchet MR, McNagny KM. 2009. Stem cells, inflammation and allergy. Allergy Asthma Clin Immunol 5:13.
5. Bonello S, Zähringer C, BelAiba RS, et al. 2007. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol 27:755-761.
6. Brabin B. 1997. Malaria in pregnancy: current issues. Afr Health 19:19-20.
7. Brabin B, Piper C. 1997. Anaemia- and malaria-attributable low birthweight in two populations in Papua New Guinea. Ann Hum Biol 24:547-555.
8. Brewer T, Grate S, Peggins J, et al. 1994a. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 51:251-259.
9. Brewer T, Peggins J, Grate S, et al. 1994b. Neurotoxicity in animals due to arteether and artemether. Trans R Soc Trop Med Hyg 88:S33-S36.
10. Bunn HF, Poyton RO. 1996. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76:839-885.
11. Cai J, Yang J, Jones DP. 1998. Mitochondrial control of apoptosis: the role of cytochrome c. Biochim Biophys Acta 1366:139-149.
12. Chaudhri G, Clark IA, Hunt NH, et al. 1986. Effect of antioxidants on primary alloantigen-induced T cell activation and proliferation. J Immunol 137:2646-2652.
13. Chen KC, Zhou Y, Zhang W, Lou MF. 2007. Control of PDGF-induced reactive oxygen species (ROS) generation and signal transduction in human lens epithelial cells. Mol Vis 13:374-387.
14. China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials. 1982. Studies on the toxicity of Qinghaosu and its derivatives. J Tradit Chin Med 2:31-36.
15. Clark RL. 2009. Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod Toxicol 28:285-296.
16. Clark RL, White T, Clode S, et al. 2004. Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. Birth Defects Res B Dev Reprod Toxicol 71:380-394.
17. Clark RL, Arima A, Kumemura M, et al. 2008a. Artesunate: developmental toxicity and toxicokinetics in monkeys. Birth Defects Res B Dev Reprod Toxicol 83:418-434.
18. Clark RL, Lerman SA, Cox EM, White TE. 2008b. Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes and relationship to reticulocyte count. Birth Defects Res B Dev Reprod Toxicol 83:397-406.
19. Clark RL, Gristwood WE, Lewsley R, et al. 2010. Localization of artesunate and its derivatives in the pregnant rat and fetus following oral administration and relationship to developmental toxicity. Birth Defects Res B Dev Reprod Toxicol 89:364-375.
20. Coghi P, Basilico N, Taramelli D, et al. 2009. Interaction of artemisinins with oxyhemoglobin Hb-FeII, Hb-FeII, carboxyHb-FeII, heme-FeII, and carboxyheme FeII: significance for mode of action and implications for therapy of cerebral malaria. Chem Med Chem 4:2045-2053.
21. Cui L, Su XZ. 2009. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther 7:999-1013.
22. Deen JL, von Seidlein L. 2002. Antimalarial use during pregnancy and its effect on birthweight. Trans R Soc Trop Med Hyg 96:573-574.
23. Deen JL, von Seidlein L, Pinder M, et al. 2001. The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Trans R Soc Trop Med Hyg 95:424-428.
24. Derelanko MJ. 1987. Determination of erythrocyte life span in F-344, Wistar, and Sprague-Dawley rats using a modification of the [3H]diisopropylfluorophosphate ([3H]DFP) method. Fundam Appl Toxicol 9:271-276.
25. Du JH, Zhang HD, Ma ZJ, Ji KM. 2010. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol 65:895-902.
26. Efferth T, Giaisi M, Merling A, et al. 2007. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One 2:e693.
27. Fidelus RK. 1988. The generation of oxygen radicals: a positive signal for lymphocyte activation. Cell Immunol 113:175-182.
28. Finkel T. 1998. Oxygen radicals and signaling. Curr Opin Cell Biol 10:248-253.
29. Finkel T. 2001. Reactive oxygen species and signal transduction. IUBMB Life 52:3-6.
30. Fried M, Duffy PE. 1996. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 7:1502-1504.
31. Genovese R, Newman D, Brewer T. 2000. Behavioral and neural toxicity of the artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats. Pharmacol Biochem Behav 67:37-44.
32. Granja AC, Machungo F, Gomes A, et al. 1998. Malaria-related maternal mortality in urban Mozambique. Ann Trop Med Parasitol 92:257-263.
33. Green DR, Reed JC. 1998. Mitochondria and apoptosis. Science 281:1309-1312.
34. Gronowicz G, Swift H, Steck TL. 1984. Maturation of the reticulocyte in vitro. J Cell Sci 71:177-197.
35. Guerin PJ, Olliaro P, Nosten F, et al. 2002. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2:564-573.
36. Halliwell B, Gutteridge J. 2007. Free radicals in biology and medicine. Oxford: Oxford University Press. pp. 111, 189, 199, 206.
37. Hardy K, Hunt NH. 2004. Effects of a redox-active agent on lymphocyte activation and early gene expression patterns. Free Radic Biol Med 37:1550-1563.
38. 2+-mediated decomposition, PfATP6 binding, and antimalarial activities of artemisone and other artemisinins: the unlikelihood of C-centered radicals as bioactive intermediates. Chem Med Chem 2:1480-1497.
39. Hehner SP, Breitkreutz R, Shubinsky G, et al. 2000. Enhancement of T cell receptor signaling by a mild oxidative shift in the intracellular thiol pool. J Immunol 165:4319-4328.
40. Huang LE, Arany Z, Livingston DM, Bunn HF. 1996. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem 271:32253-32259.
41. Huang XJ, Ma ZQ, Zhang WP, et al. 2007. Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. J Pharm Pharmacol 59:849-856.
42. Hwang C, Sinskey AJ, Lodish HF. 1992. Oxidized redox state of glutathione in the endoplasmic reticulum. Science 257:1496-1502.
43. Ilett KF, Batty KT. 2005. Artemisinin and its derivatives. In: Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, editors. Antimicrobial therapy and vaccines-Volume II: antimicrobial agents. 2nd ed. Pittsburgh: ESun Technologies. pp. 981-1002 (ISBN: 0-9744641-1-2).
44. Institute of Laboratory Animal Resources Commission on Life Sciences and the National Research Council. 1996. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press.
45. Ittarat W, Sreepian A, Srisarin A, Pathepchotivong K. 2003. Effect of dihydroartemisinin on the antioxidant capacity of P. falciparum-infected erythrocytes. Southeast Asian J Trop Med Public Health 34:744-750.
46. Jollie WP. 1990. Development, morphology, and function of the yolk-sac placenta of laboratory rodents. Teratology 41:361-381.
47. Kane DJ, Sarafian TA, Anton R, et al. 1993. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 262:1274-1277.
48. Kaufman R. 1999. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 13:1211-1233.
49. Kaushansky K. 2006. Lineage-specific hematopoietic growth factors. N Engl J Med 354:2034-2045.
50. Kawamura S, Yoshioka T, Kato T, et al. 1996. Histological changes in rat embryonic blood cells as a possible mechanism for ventricular septal defects produced by an N-phenylimide herbicide. Teratology 54:237-244.
51. Kietzmann T, Fandrey J, Acker H. 2000. Oxygen radicals as messengers in oxygen-dependent gene expression. News Physiol Sci 15:202-208.
52. Kirchgatter K, Del Portillo HA. 2005. Clinical and molecular aspects of severe malaria. An Acad Bras Cienc 77:455-475.
53. Knights P. 2002a. Artesunate: 14 day preliminary oral (gavage administration) toxicity study in the rat. Covance Report Number 1552/051-D6154.
54. Knights P. 2002b. Artesunate: 4 week oral (gavage administration) toxicity study in the rat. Covance Report Number 1552/059-D6154.
55. Koury MJ, Koury ST, Kopsombut P, Bondurant MC. 2005. In vitro maturation of nascent reticulocytes to erythrocytes. Blood 105:2168-2174.
56. Krantz SB. 1991. Erythropoietin. Blood 77:419-434.
57. Kreil A, Wenisch C, Brittenham G, et al. 2000. Thrombopoietin in Plasmodium falciparum malaria. Br J Haematol 109:534-536.
58. Krungkrai SR, Yuthavong Y. 1987. The antimalarial action on Plasmodium falciparum of qinghaosu and artesunate in combination with agents which modulate oxidant stress. Trans R Soc Trop Med Hyg 81:710-714.
59. Laffan SB, James AC, Maleef BE, et al. 2006. Mitochondrial involvement of artesunate toxicity in rat embryonic erythroblasts. Birth Defects Res A Clin Mol Teratol 76:329.
60. Lang KS, Lang PA, Bauer C, et al. 2005. Mechanisms of suicidal erythrocyte death. Cell Physiol Biochem 15:195-202.
61. Levander OA, Ager Jr AL, Morris VC, May RG. 1989. Qinghaosu, dietary vitamin E, selenium, and cod-liver oil: effect on the susceptibility of mice to the malarial parasite Plasmodium yoelii. Am J Clin Nutr 50:346-352.
62. Li QC, Peggins J, Fleckenstein L, et al. 1998. The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. J Pharm Pharmacol 50:173-182.
63. Li Q, Brueckner R, Peggins J, et al. 1999. Arteether toxicokinetics and pharmacokinetics in rats after 25mg/kg/day single and multiple doses. Eur J Drug Metab Pharmacokinet 24:213-223.
64. Li Q, Mog S, Si Y, et al. 2002. Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents. Am J Trop Med Hyg 66:516-525.
65. Li Q, Xie LH, Si Y, et al. 2005. Toxicokinetics and hydrolysis of artelinate and artesunate in malaria-infected rats. Int J Toxicol 24:241-250.
66. Liberati TA, Sansone SR, Feuston MH. 2004. Hematology and clinical chemistry values in pregnant Wistar Hannover rats compared with nonmated controls. Vet Clin Pathol 33:68-73.
67. Lim P, Alker AP, Khim N, et al. 2009. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J 8:11.
68. Lin AJ, Zikry AB, Kyle DE. 1997. Antimalarial activity of new dihydroartemisinin derivatives. 7. 4-(p-Substituted phenyl)-4(R or S)-[10(α or β)-dihydroartemisininoxy]butyricAcids. J Med Chem 40:1396-1400.
69. Linsley PS, Ledbetter JA. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11:191-212.
70. Longo M, Zanoncelli S, Torre PD, et al. 2006. In vivo and in vitro investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos. Reprod Toxicol 22:797-810.
71. Longo M, Zanoncelli S, Della Torre P, et al. 2008. Investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) using the Frog Embryo Teratogenesis Assay-Xenopus (FETAX). Reprod Toxicol 25:433-441.
72. Lurie S, Danon D. 1992. Life span of erythrocytes in late pregnancy. Obstet Gynecol 80:123-126.
73. Majoul I, Ferrari D, Söling HD. 1997. Reduction of protein disulfide bonds in an oxidizing environment. The disulfide bridge of cholera toxin A-subunit is reduced in the endoplasmic reticulum. FEBS Lett 401:104-108.
74. Malassiné A, Frendo JL, Evain-Brion D. 2003. A comparison of placental development and endocrine functions between the human and mouse model. Hum Reprod Update 9:531-539.
75. Maleeff BE, James AC, Laffan SB, et al. 2007. In vitro effects of artesunate on rat embryonic and fetal blood cells. Microsc Microanal 13:1698-1699.
76. Menendez C. 2006. Malaria during pregnancy. Curr Mol Med 6:269-273.
77. Mercer AE. 2009. The role of bioactivation in the pharmacology and toxicology of the artemisinin-based antimalarials. Curr Opin Drug Discov Devel 12:125-132.
78. Meshnick SR. 2002. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 32:1655-1660.
79. Meshnick SR, Tsang TW, Lin FB, et al. 1989. Activated oxygen mediates the antimalarial activity of qinghaosu. Prog Clin Biol Res 313:95-104.
80. Meshnick SR, Taylor TE, Kamchonwongpaisan S. 1996. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 60:301-315.
81. Novogrodsky A, Ravid A, Rubin AL, Stenzel KH. 1982. Hydroxyl radical scavengers inhibit lymphocyte mitogenesis. Proc Natl Acad Sci USA 79:1171-1174.
82. Olliaro PL, Haynes RK, Meunier B, Yuthavong Y. 2001. Possible modes of action of the artemisinin-type compounds. Trends Parasitol 17:122-126.
83. Parapini S, Basilico N, Mondani M, et al. 2004. Evidence that haem iron in the malaria parasite is not needed for the antimalarial effects of artemisinin. FEBS Lett 575:91-42.
84. Petras J, Young G, Bauman R, et al. 2000. Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular nuclei, paramedian reticular nuclei, and perihypoglassal nuclei. Anat Embryol 201:383-397.
85. Posobiec LM, Bushdid PB, Laffan SB, et al. 2007. Dihydroartemisinin (DHA) treatment causes decreased proliferation and apoptosis in rat embryonic erythroblasts in whole embryo culture. Birth Defects Res A Clin Mol Teratol 79:361.
86. Rhee SG. 1999. Redox signaling: hydrogen peroxide as intracellular messenger. Expt Mol Med 31:53-59.
87. Rogers WO, Sem R, Tero T, et al. 2009. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 8:10.
88. Sachs J, Malaney P. 2002. The economic and social burden of malaria. Nature 415:680-685.
89. Sattler M, Winkler T, Verma S, et al. 1999. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood 93:2928-2935.
90. Sauer H, Wartenberg M, Hescheler J. 2001. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 11:173-186.
91. Schalm OW, Jain NC, Carroll EJ. 1975. Veterinary hematology. 3rd ed. Philadelphia: Lea and Febiger. p. 243.
92. Schmuck G, Roehrdanz E, Haynes RK, Kahl R. 2002. Neurotoxic mode of action of artemisinin. Antimicrob Agents Chemother 46:821-827.
93. Semenza GL. 2004. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology 19:176-182.
94. Senok AC, Nelson EA, Li K, Oppenheimer SJ. 1997. Thalassaemia trait, red blood cell age and oxidant stress: effects on Plasmodium falciparum growth and sensitivity to artemisinin. Trans R Soc Trop Med Hyg 91:585-589.
95. Si Y, Zeng Q, Zhang J, et al. 2004. Evaluation of the embryonic toxicity of artesunate in rats. Am J Trop Med 71:260.
96. Si Y, Li Q, Xie L, et al. 2007. Neurotoxicity and toxicokinetics of artelinic acid following repeated oral administration in rats. Int J Toxicol 26:401-410.
97. Smith SL, Sadler CJ, Dodd CC, et al. 2001. The role of glutathione in the neurotoxicity of artemisinin derivatives in vitro. Biochem Pharmacol 61:409-416.
98. Snow RW, Guerra CA, Noor AM, et al. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214-217.
99. Steketee RW, Nahlen BL, Parise ME, Menendez C. 2001. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 64:28-35.
100. Suh KN, Keystone JS. 1996. Malaria prophylaxis in pregnancy and children. Infect Dis Clin Pract 5:541-546.
101. Sundaresan M, Yu ZX, Ferrans VJ, et al. 1995. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 270:296-299.
102. Taylor SM, Juliano JJ, Meshnick SR. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:1807.
103. Testa U. 2004. Apoptotic mechanisms in the control of erythropoiesis. Leukemia 18:1176-1199.
104. Torres M, Forman HJ. 2003. Redox signaling and the MAP kinase pathways. Biofactors 17:287-296.
105. Weatherall DJ, Miller LH, Baruch DI, et al. 2002. Malaria and the red cell. Hematology Am Soc Hematol Educ Program 35-57.
106. Weina PJ, Haeberle AS, Milhous WK. 2006. Intravenous artesunate: the new generation of lifesaving treatment for severe malaria in the warfighter. Walter Reed Army Institute of Research, Silver Spring, MD. Report from Stormingmedia.us.
107. White TE, Clark RL. 2008. Sensitive periods for developmental toxicity of orally administered artesunate in the rat. Birth Defects Res B Dev Reprod Toxicol 83:407-417.
108. White TEK, Bushdid PB, Ritter S, et al. 2006. Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivo. Birth Defects Res B Dev Reprod Toxicol 77:413-429.
109. White TE, Lordi AW, Bushdid PB, et al. 2007. Autoradiography reveals specific targeting of embryonic and fetal blood cells by the anti-malarial, artesunate. Birth Defects Res A Clin Mol Teratol 79:362.
110. Wongsrichanalai C, Meshnick SR. 2008. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis 14:716-719.
111. World Health Organization Guidelines for the treatment of malaria. 2006. At WHO website. p.17
112. Wu WM, Wu Y, Wu YL, et al. 1998. Unified mechanistic framework for the Fe(II)-induced cleavage of qinghaosu and derivatives/analogues: the first spin-trapping evidence for the previously postulated secondary C-4 radical. J Am Chem Soc 120:3316-3325.
113. Xie LH, Johnson TO, Weina PJ, et al. 2005. Risk assessment and therapeutic indices of artesunate and artelinate in Plasmodium berghei-infected and uninfected rats. Int J Toxicol 24:251-264.
114. Yuan X, Cong Y, Hao J, et al. 2004. Regulation of LIP level and ROS formation through interaction of H-ferritin with G-CSF receptor. J Mol Biol 339:131-144.
115. Zucker RM, Elstein KH, Shuey DL, Rogers JM. 1995. Flow cytometric detection of abnormal fetal erythropoiesis: application to 5-fluorouracil-induced anemia. Teratology 51:37-44.